Regional rights for taletrectinib
HANGZHOU, China & NEW YORK—Clinical-stage oncology company AnHeart Therapeutics Co. Ltd. has outlicensed clinical development and commercialization rights to taletrectinib to NewG Lab Co. Ltd. via AnHeart Therapeutics Inc., its subsidiary. Taletrectinib, a next-generation ROS1 and NTRK inhibitor that can cross the blood-brain barrier, has been assessed for safety and efficacy in Phase 1 clinical trials in Japan and the United States, and has advanced into Phase 2 trials. Under the terms of the agreement, AnHeart stands to receive $7 million in milestone payments and royalty payments in the double digits. NewG Lab will take over development, market authorization and commercialization for the compound in Korea, and will join the Phase 2 clinical trial for taletrectinib in non-small cell lung cancer with ROS1/NTRK mutations.